Literature DB >> 17283166

Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.

Aoshuang Chen1, Shanrong Liu, David Park, Youmin Kang, Guoxing Zheng.   

Abstract

One strategy for improving adoptive therapy is preconditioning the host immune environment by depleting CD4(+)CD25(+) regulatory T cells (Treg) suppressive to antitumor responses. Given that Treg increase, or selectively accumulate, within tumors and are sensitive to FasL-mediated apoptosis, we test here the hypothesis that inducing apoptosis of intratumoral Treg using FasL may improve adoptive T cell therapy. We show that FasL applied intratumorally via protein transfer decreases intratumoral Treg via inducing apoptosis in these cells. Significantly, we show that the use of FasL prior to the infusion of tumor-reactive CD8(+) T cells enhances the therapeutic efficacy of adoptive T cell transfer against established tumors, which is mediated by persistent, systemic antitumor immunity. Intratumoral FasL protein transfer also results in neutrophil infiltration of tumor. However, we show that intratumoral immunodepletion of neutrophils does not abolish the effect of FasL on adoptive transfer. Rather, the effect of FasL is completely abolished by cotransfer of Treg, isolated from the tumor-draining lymph nodes. Hence, our study shows for the first time that using FasL to predeplete intratumoral Treg provides a useful means for optimizing adoptive therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283166     DOI: 10.1158/0008-5472.CAN-06-2622

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Authors:  Esma S Yolcu; Hong Zhao; Laura Bandura-Morgan; Chantale Lacelle; Kyle B Woodward; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

Review 2.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3.

Authors:  Saul J Priceman; Shudan Shen; Lin Wang; Jiehui Deng; Chanyu Yue; Maciej Kujawski; Hua Yu
Journal:  Cell Rep       Date:  2014-03-13       Impact factor: 9.423

Review 4.  Is cancer vaccination feasible at older age?

Authors:  Claudia Gravekamp; Arthee Jahangir
Journal:  Exp Gerontol       Date:  2014-02-06       Impact factor: 4.032

Review 5.  The impact of aging on cancer vaccination.

Authors:  Claudia Gravekamp
Journal:  Curr Opin Immunol       Date:  2011-07-18       Impact factor: 7.486

Review 6.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma.

Authors:  Yi-Ling Chen; Jung-Hua Fang; Ming-Derg Lai; Yan-Shen Shan
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

8.  Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.

Authors:  Jonathan M Weiss; Jeff J Subleski; Tim Back; Xin Chen; Stephanie K Watkins; Hideo Yagita; Thomas J Sayers; William J Murphy; Robert H Wiltrout
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

Review 9.  DNA vaccines: developing new strategies against cancer.

Authors:  Daniela Fioretti; Sandra Iurescia; Vito Michele Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-03-28

Review 10.  Aging and cancer vaccines.

Authors:  Claudia Gravekamp; Dinesh Chandra
Journal:  Crit Rev Oncog       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.